Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen formula + dehydroepiandrosterone is an investigational combination therapy being developed by Jiangxi University of Traditional Chinese Medicine for the treatment of diminished ovarian reserve (DOR) in women. The therapy integrates traditional Chinese medicine (TCM) with Western hormonal supplementation. It consists of a 'Bushen' (kidney-tonifying) formula—specifically the Bushen Yiqi formula or Bushen Yuyin Tiaochong Decoction—paired with dehydroepiandrosterone (DHEA), a steroid hormone precursor. DHEA is converted into androgens and estrogens within the ovarian follicles, which is thought to enhance folliculogenesis and improve the ovarian microenvironment. The TCM component aims to regulate the hypothalamic-pituitary-ovarian axis and improve reproductive health according to traditional principles. Clinical trials evaluate the combination's ability to improve fertility markers, including anti-Müllerian hormone (AMH) levels, follicle-stimulating hormone (FSH) levels, and antral follicle count (AFC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen formula + dehydroepiandrosterone.